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EQ-5D  is used  in cost-effectiveness  studies  underlying  many  important  health  policy  decisions.  It com-
prises  a survey  instrument  describing  health  states  across  ﬁve  domains,  and  a system  of  utility values
for  each  state.  The  original  3-level  version  of  EQ-5D  is being  replaced  with  a more  sensitive  5-level  ver-
sion  but  the  consequences  of  this  change  are  uncertain.  We  develop  a multi-equation  ordinal  response
model  incorporating  a copula  speciﬁcation  with  normal  mixture  marginals  to analyse  joint  responses
to  EQ-5D-3L  and  EQ-5D-5L  in  a  survey  of  people  with  rheumatic  disease,  and  use  it to  generate  map-
pings  between  the  alternative  descriptive  systems.  We  revisit  a  major  cost-effectiveness  study  of  drug
therapies  for  rheumatoid  arthritis,  mapping  the  original  EQ-5D-3L  measure  onto  a 5L  valuation  basis.
Working  within  a comprehensive,  ﬂexible  econometric  framework,  we  ﬁnd  that  use  of  simpler  restricted
speciﬁcations  can  make  very  large  changes  to cost-effectiveness  estimates  with  serious  implications  for
decision-making.
© 2017  The  Authors.  Published  by  Elsevier  B.V.  This  is  an open  access  article  under  the  CC  BY  licenseQ-5D
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. Introduction: EQ-5D-3L and EQ-5D-5L
The quality-adjusted life year (QALY) is one of the most widely
sed health beneﬁt measures in economic evaluations of inter-
entions, services or programmes designed to improve health. The
ALY reﬂects concerns for both quality and length of life and allows
ealth care decision makers to use a consistent approach across a
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tanding Society project and the Centre for Micro-Social Change (grants
S/K005146/1 and ES/L009153/1). We thank Kaleb Michaud (University of Nebraska
edical Center and National Data Bank for Rheumatic Diseases) and Frederick Wolfe
National Data Bank for Rheumatic Diseases) for providing the data, and the editor
nd three anonymous referees, Andrew Jones, Anastasios Panagiotelis, Allan Wailoo
nd  David Zimmer for many helpful comments. The views expressed in this article,
nd any errors or omissions, are ours only.
∗ Corresponding author at: ScHARR, University of Shefﬁeld, Regent Court, 30
egent Street, Shefﬁeld S1 4DA, UK.
E-mail address: steve.pudney@shefﬁeld.ac.uk (S. Pudney).
ttp://dx.doi.org/10.1016/j.jhealeco.2017.06.013
167-6296/© 2017 The Authors. Published by Elsevier B.V. This is an open access article ubroad range of disease areas, treatments, and patients. QALY esti-
mation is based on patient-reported outcome measures (PROMs),
of which EQ-5D is a leading example. EQ-5D is recommended by
the English National Institute for Health and Care Excellence (NICE)
for its technology appraisals, but it has wider international signiﬁ-
cance: public bodies in at least ten other countries also recommend
EQ-5D as a basis for cost-effectiveness analysis.1 It is also increas-
ingly used as a measure of performance in wider economic contexts,
and as a generic health measure in population surveys (Devlin and
Brooks, 2017). There is continuing debate about the basis of eco-
nomic appraisal in health policy, with interest in wider outcome
measures based on wellbeing or capabilities, income-variation val-
uations, and the use of weights for different aspects of disease such
as burden of disease or rarity (Brazier and Tsuchiya, 2015). Nev-
1 Including Belgium, Colombia, Egypt, Estonia, Ireland, Latvia, Lithuania, the
Netherlands, New Zealand and Sweden. See the pharmacoeconmics guidelines
maintained by the International Society for Pharmacoeconomics and Outcomes
Research (https://www.ispor.org/PEguidelines/COMP3.asp).
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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rtheless, for the foreseeable future, it seems inevitable that cost
er QALY will continue to be the main driver of decisions in many
ublic health services around the world.
EQ-5D measures patient outcomes across ﬁve dimensions:
obility, self-care, usual activities, pain/discomfort, and anxi-
ty/depression. The original version of EQ-5D, which has been used
n a large number of cost-effectiveness evaluations, measures each
omain on a scale with three severity levels (no problems, some
r moderate problems, extreme problems). Up to 35 = 243 states of
ealth can be described in this way, and each has been assigned a
tility score on the basis of an analysis of preferences over length
nd quality of life using data from the general public (Dolan, 1997);
ull health is assigned a utility score of 1, 0 is equivalent to death,
nd negative values indicate health states worse than death.
Concerns about (lack of) sensitivity and ﬂoor/ceiling effects in
he standard version recently led to the development of a new ver-
ion, the EQ-5D-5L. The descriptive system covers the same ﬁve
imensions but the number of levels within each dimension has
een extended from three to ﬁve (no problems, slight problems,
oderate problems, severe problems, extreme problems). In addi-
ion, some of the wording has been modiﬁed to aid consistency
nd understanding.2 The maximum number of health states that
an be described with the new version is 55 = 3125. Several studies
ave reported better measurement properties in moving from the
Q-5D-3L to EQ-5D-5L in both speciﬁc patient and general popu-
ation samples (Pickard et al., 2007; Janssen et al., 2013; Scalone
t al., 2013; Agborsangaya et al., 2014; Jia et al., 2014). Utility value
ets for EQ5D-5L have been proposed for England (Devlin et al.,
016), Japan (Ikeda et al., 2015), Canada (Xie et al., 2016), Uruguay
Augustovski et al., 2016), Netherlands (Versteegh et al., 2016) and
orea (Kim et al., 2016) and similar work is underway in many other
ountries. Many studies now include EQ-5D-5L instead of the stan-
ard version. Since these studies will form part of the evidence in
uture economic evaluations, it is important to assess the likely con-
equences for economic evaluation decisions of moving across the
wo different versions of EQ-5D, and to develop a basis for using
he very large stock of existing evidence based on the 3L version.
If both variants of the EQ-5D instrument are observed in the
ame dataset and a utility score is available for each, it is possi-
le to use a conditional statistical model to map  directly from the
L utility score to the 5L score or vice versa. However, that direct
pproach has three major disadvantages. First, utility scores have
ighly irregular empirical distributions and the most widely used
apping methods often ﬁt poorly (Hernández-Alava et al., 2012).
econd, use of a single utility score to summarise the 5-dimensional
bserved response fails to exploit all of the information contained
n the observed EQ-5D responses. Third, the direct approach is nec-
ssarily speciﬁc to the particular scoring system used to construct
tility values for the 3L and 5L health descriptions, making it hard
o explore sensitivity to variations in the choice of scoring system.
he alternative approach known as ‘response mapping’ (Gray et al.,
006) models the statistical relationship between the 3L and 5L
esponses and only brings utility scoring in at the ﬁnal stage. By
eparating the logically distinct components of health state mea-
urement and utility scoring, response mapping gives (in our view)
 more natural way to proceed.
Although statistical mapping is often treated as a routine and
rcane statistical task, it can have a critical impact on the outcome of
conomic decision-making, and the econometric assumptions used
or mapping between alternative PROMs need to be examined very
arefully. Those assumptions include: the choice of covariates for
2 See the EuroQol website http://www.euroqol.org/eq-5d-products/how-to-
btain-eq-5d.html for examples of the question wording used in EQ-5D-3L and
Q-5D-5L.ealth Economics 55 (2017) 139–152
the mapping model, distributional speciﬁcation, and independence
or dependence of responses across the ﬁve domains of EQ-5D.
Various statistical speciﬁcations appear in the small existing lit-
erature. Some authors have assumed conditional independence
between the ﬁve domains of EQ-5D, estimating a separate model
for each domain. Using this approach, van Hout et al. (2012) devel-
oped a mapping between EQ-5D-3L and EQ-5D-5L to construct
an interim scoring system for EQ-5D-5L derived from the Dolan
(1997) scores for EQ-5D-3L. However, independence is an implau-
sible assumption: medical conditions may  simultaneously affect
multiple aspects of life – for instance severe pain may be accom-
panied by depression and curtailment of activities. Also, there may
be individual-speciﬁc styles of questionnaire response which affect
responses in all domains – some people tend to look on the bright
side, while others do not. The conventional normality assumption
built into the univariate or multivariate ordered probit model is also
a strong one, and consistent estimation is not achieved in general
if error distributions are non-normal, even if the model is correctly
speciﬁed in all other respects. In Section 3 of the paper, we  develop
a multi-equation model that allows for the discrete EQ-5D response
scales and uses a ﬂexible mixture-copula speciﬁcation of the error
distributions. Importantly, we  do not impose the assumption that
responses in the ﬁve domains of EQ-5D are statistically indepen-
dent. In Section 4, we  apply the model to investigate the consistency
of the responses to the two descriptive systems and the implied dif-
ferences in the utility values. We derive the appropriate mapping
technique in Section 5 and compare the results from mapping in
both directions between the two  variants of the EQ-5D instrument.
To explore the implications of modelling strategy for real-world
policy decisions, we report an application to cost-effectiveness of
treatments for rheumatoid arthritis (RA). We focus on RA partly for
its inherent importance – among the 291 medical conditions cov-
ered by the 2010 Global Burden of Disease Study (Murray, 2012), RA
ranked as the 42nd greatest contributor to global disability, mea-
sured in Years Lived with Disability (YLD), ranking immediately
after malaria. It is also a rapidly growing problem; between 1990
and 2010, the estimated global burden of RA (adjusted for popu-
lation growth and ageing) grew 15% in terms of YLD and 44% in
terms of disability-adjusted life years (Cross et al., 2014). But data
availability is another advantage; we  have access to the National
Data Bank for Rheumatic Diseases (NDB), which provides a unique
RA-speciﬁc reference dataset that observes both versions of EQ-5D
and also contains detailed clinical outcome measures. This allows
us to explore one of the most important features of the mapping
process, by varying the information provided by the covariates of
the mapping model.
In Section 6, we re-visit the important CARDERA cost-
effectiveness study (Choy et al., 2008; Wailoo et al., 2014)
comparing four drug therapies for RA. We use statistical mapping
to convert EQ-5D-3L responses into EQ-5D-5L QALYs, and ﬁnd a
large impact of the choice of statistical assumptions on the evalua-
tion results. Our evidence suggests that the potential to move from
EQ-5D-3L to EQ-5D-5L will pose signiﬁcant methodological ques-
tions and may  raise questions about some past decisions. We  begin
in Section 2 by describing the NDB data that we use for the EQ-5D-
3L and EQ-5D-5L comparison – one of the few datasets available
in which both variants of the instrument are carried in the same
questionnaire.2. The NDB dataset
The NDB is a register of patients with rheumatoid disease, pri-
marily recruited by referral from US and Canadian rheumatologists.
Information supplied by participants is validated by direct refer-
M. Hernández-Alava, S. Pudney / Journal of Health Economics 55 (2017) 139–152 141
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Nig. 1. Response histograms for EQ-5D-3L and EQ-5D-5L (Jan 2011 wave of NDB,
 = 5192).
nce to records held by hospitals and physicians.3 Full details of
he recruitment process are given by Wolfe and Michaud (2011).
he EQ-5D responses and other patient-supplied data are collected
y various means, primarily postal and web-based questionnaires
ompleted directly by patients. Data collection began in 1998 and
ontinues to the present, in waves administered in January and July
f each year. In 2011, there was a switch from 3L to the 5L version
f EQ-5D and both versions were collected in parallel during the
anuary 2011 wave, to allow the effects of the switch to be accom-
odated in analyses spanning the whole period. Our principal aim
s to use data from that wave of the survey to estimate a joint model
f the 3- and 5L responses, which can then be used to map  from
- to 5L EQ-5D during the pre-2011 period and from 5- to 3L EQ-
D after January 2011. It then becomes possible to investigate the
onsistency of the two versions of EQ-5D and assess the impact of
apping between them.
.1. EQ-5D response distributions
Fig. 1 shows histograms of the NDB sample response distribu-
ions for the 3- and 5L versions of each domain of EQ-5D. There are
lear differences between the distributional shapes for different
omains: self-care and anxiety/depression have a dominant mode
t the ﬁrst category; the mobility and usual activities domains also
3 A minority of cases come by self-referral, with medical details obtained by
DBRB in the same way.Fig. 2. Smoothed empirical distributions of EQ-5D-3L and EQ-5D-5L (Jan 2011 wave
of  NDB, n = 5192).
have a decreasing proﬁle but with a heavier central section, while
the pain/discomfort domain shows a strong mode in the centre
of the distribution. This variation in the shape of the component
distributions underlines the need to use a suitably ﬂexible model
speciﬁcation to analyse the relationship between variants of EQ-5D.
2.2. Utility scores
For each possible combination of EQ-5D responses, there is a
utility value which allows overall health-related quality of life to
be estimated and compared across individuals and conditions. We
use the value sets produced by Dolan (1997) and Devlin et al. (2016)
for the 3- and 5L versions of the instrument which, at present,
are the standard choices for QALY measurement in England. Dolan
(1997) used data from a representative sample of the UK popula-
tion (2977 respondents). Each respondent valued 13 hypothetical
health states using the time trade-off (TTO) method, generating
valuations for a subsample of 42 of the 243 health states described
by the EQ-5D-3L. The data were then modelled using regression
methods to impute utility values for the remaining health states.
Devlin et al. (2016) used a sample of the English population (996
respondents) who valued ten health states using a composite TTO
approach, and seven paired comparisons of health states via dis-
crete choice experiment tasks. The model selected for the EQ-5D-5L
value set for England was  a hybrid model using both sets of data
(Feng et al., 2016).
Fig. 2 shows kernel density estimates of the distributions of util-
ity scores in the NDB data, aggregated across all ﬁve domains. The
distribution is smoother for the 5L version, particularly towards
the top of the range, and this ﬁner structure is a major reason for
its adoption in practice. The distribution of utility scores for the
3L version of EQ-5D has two particularly worrying features. There
are ranges with probability mass at or close to zero, particularly
around 0.8–1.0 and 0.3–0.45. Consequently, methods for mapping
to and from EQ-5D-3L which implicitly assume a smooth positive
density can give very poor results (Hernández-Alava et al., 2012).
The second striking feature of the distribution for EQ-5D-3L is the
large group of cases with utility values close to zero, implying that
a non-negligible proportion of patients with rheumatoid arthritis
(RA) are in a state comparable to, or worse than, death. The out-
comes of evaluation studies often rest on the ability of a therapy
to improve quality of life for patients in very poor health, so the
(perhaps implausibly) large frequency of such cases is a potential
source of bias in NICE recommendations.
Table 1 summarises the January 2011 NDB data on the value
scores for the two variants of EQ-5D in terms of their correlation
142 M. Hernández-Alava, S. Pudney / Journal of H
Table  1
Spearman correlations of 3- and 5L EQ-5D (Jan 2011 wave of NDB, n = 4856).
Variable EQ-5D-3L EQ-5D-5L
EQ-5D-3L 1.000 0.845
EQ-5D-5L 0.845 1.000
Female −0.054 −0.074
Age  0.030 0.060
HAQ score (0–3) −0.735 −0.758
Pain scale (0–10) −0.707 −0.704
Overall RADAI score −0.737 −0.746
Global severity (0–10) −0.698 −0.721
Disease duration (months) −0.057 −0.063
Fatigue scale (0–10) −0.633 −0.669
Sleep disturbance scale (0–10) −0.506 −0.541
Arthritis activity (general) −0.611 −0.626
Arthritis activity (today) −0.672 −0.673
RADAI joints (score) −0.641 −0.648
RADAI joints (count) −0.581 −0.589
Morning stiffness (0–6) −0.538 −0.554
Co-morbidity index (0–9) −0.344 −0.360
Physical component score (SF-6D) 0.727 0.700
Mental component score (SF-6D) 0.475 0.569
Health satisfaction (0–4) −0.638 −0.671
Table 2
Means of EQ-5D-3L and EQ-5D-5L utility scores by severity of condition (Jan 2011
wave of NDB, n = 5192).
3L 5L Ratio
Overall 0.68 0.78 0.87
By general severity (HAQ) and pain scale category
Generala Painb 3L 5L Ratio
1  1 0.87 0.92 0.95
1  2 0.76 0.86 0.89
1  3 0.72 0.83 0.87
1  4 0.67 0.78 0.87
1  5 0.51 0.72 0.71
2  1 0.74 0.81 0.91
2  2 0.66 0.76 0.87
2  3 0.60 0.73 0.82
2  4 0.52 0.64 0.81
2  5 0.30 0.53 0.56
3  1 0.63 0.71 0.89
3  2 0.54 0.65 0.83
3  3 0.45 0.57 0.79
3  4 0.35 0.48 0.73
3  5 0.15 0.35 0.43
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(Groups corresponding to HAQ scores (1) [0–1); (2) [1–2) and (3) [2–3].
b Groups corresponding to pain scores (1) [0–2); (2) [2–4); (3) [4–6); (4) [6–8) and
5)  [8–10].
ith each other, with basic demographic characteristics, and with
 set of clinical outcome measures. We  use the Spearman rank cor-
elation to show the strength of monotonic, not necessarily linear,
ssociations, but the Pearson correlation shows a similar picture.
here is a high correlation between the two variants of EQ-5D, but
he 5L version has greater sensitivity, since correlations with demo-
raphics and clinical outcomes (in the lower panels of Table 1) are
niformly higher for EQ-5D-5L.
Table 2 shows that there is a systematic difference in the 3L and
L utility scores, with the old system generating utilities averag-
ng (in the NDB data) only 87% of the utility values given by the
ew system. This alone could make a signiﬁcant difference to some
valuation results. It would be inadvisible to address the issue with
 simple proportional adjustment, since the ratio of mean scores
s not constant but decreases as both general severity and pain
ncrease, so the differences are minor at the top end of EQ-5D and
uch larger at the bottom. Table 2 gives means classiﬁed by lev-
ls of general disability (in three groups, scores 0–1, 1–2 and 2–3)
nd pain (in ﬁve groups 0–2, 2–4, 4–6, 6–8 and 8–10), as classiﬁedealth Economics 55 (2017) 139–152
by the Stanford Health Assessment Questionnaire (HAQ). The HAQ
is widely used by clinicians to measure treatment outcomes; see
Bruce and Fries (2003) for a review.
Mapping from 3L to 5L involves two  changes: a shift from the
3L health descriptive system to the 5L system, made using a pre-
dictive statistical mapping model; and a shift from the utility tariff
developed for EQ-5D-3L to the utility tariff applicable to EQ-5D-5L.
These two  changes occur jointly, so it is not possible to disentangle
fully the effect on cost-effectiveness calculations of mapping from
the effect of the change in utility structure. However, within a ﬁxed
framework dictated by the given 3L and 5L utility tariffs, it is pos-
sible to compare the results produced by alternative speciﬁcations
of the mapping model. This is our strategy, implemented within a
comprehensive and ﬂexible econometric approach.
3. A correlated copula model with mixture marginals
Our aim is to develop an econometric model of responses to the
ten items of the 3L and 5L instruments. The speciﬁcation is guided
by six important considerations, intended to avoid unnecessarily
strong restrictions on the data. The model should:
(i) Treat the 3L and 5L responses symmetrically so that it can be
used for 3L → 5L and 5L → 3L mapping in a mutually consistent
way.
(ii) Avoid the assumption that the 5L response scale is simply a
more detailed categorisation than the 3L scale of the same
underlying concept – structural differences between the two
responses are permitted if empirically necessary.
iii) Allow for the effects of covariates – here, age, sex and clini-
cal outcome measures, without assuming that they necessarily
inﬂuence 3L and 5L responses in the same way.
(iv) Capture the strong association between 3L and 5L responses
within each health domain, without necessarily assuming that
the strength of the association is the same in all parts of the
health distribution – for example, someone who has experi-
enced extreme pain may  answer the pain questions in a more
focused and coherent way than someone without experience of
chronic pain. To achieve this, we  use a copula approach (Trivedi
and Zimmer, 2005) to specify the bivariate distribution of each
3L, 5L pair of responses.
(v) Be sufﬁciently ﬂexible to ﬁt the diverse response patterns
shown in Fig. 1, so we generalise the usual assumption of
normally-distributed errors by allowing for a 2-part normal
mixture distribution, which can capture a wide range of distri-
butional shapes.
(vi) Allow dependence across the ﬁve domains of EQ-5D, reﬂecting
common underlying causes and individual-speciﬁc response
styles; we  achieve this by incorporating a random latent factor
inﬂuencing responses in all domains.
In advance of the empirical analysis, there is no way of knowing
which of these considerations is most important, so the resulting
model is complex. Deﬁne 1 ≤ Y3id ≤ 3 and 1 ≤ Y5id ≤ 5 as the reported
outcomes for the dth domain (d = 1, . . .,  5) of the 3- and 5L forms
of EQ-5D. The model is a system of ten latent regressions, arranged
in the ﬁve domain groups, with domain d containing the equations
for Y3id and Y5id:
Y∗3id = Xiˇ3d + U3id
Y∗5id = Xiˇ5d + U5id
}
, d = 1, . . .,  5 (1)where i indexes independently sampled individuals, Xi is a col-
lection of row vectors of covariates, ˇ3d, ˇ5d are corresponding
coefﬁcient vectors and U3id, U5id are unobserved errors which may
be stochastically dependent and non-normal. The latent dependent
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evaluate the integral in (7) at each observation to give the likelihood
function.M. Hernández-Alava, S. Pudney / Journ
ariables Y∗3id, Y
∗
5id are not observed directly but they have observ-
ble ordinal counterparts, Y3id, Y5id, generated by the following
hreshold-crossing conditions:
kid = q iff kqd ≤ Y∗kid < k(q+1)d; > q = 1, . . .,  Qk; k = 3, 5 (2)
here Qk = 3 or 5 is the number of categories of Ykid and the kqd
re threshold parameters, with k1d = −∞ and k(Qk+1)d = +∞.
High-dimensional ordinal-variable applications present major
omputational problems. Currently, there is only a single published
odel of EQ-5D responses that relaxes independence (Conigliani
t al., 2015), using a 5-equation correlated multivariate ordered
robit model to predict EQ-5D responses from aggregate SF12
cores. Using that model in our 10-dimensional 3L-5L mapping
ontext would involve estimation of 45 residual covariance param-
ters, with a likelihood requiring numerical integration over a
0-dimensional rectangle. Past experience with similar maximum
imulated likelihood problems, using best-practice simulation
ethods like Halton sequences, tells us that likelihood-based tests
nd ﬁt statistics are not robust enough for model comparisons to
e reliable. The conventional ordered probit model also involves
ormality assumptions that are critical to its consistency property
nd which we want to relax.
Possible solutions to the dimensionality problem work by
mposing structure on the joint distribution of the latent Y∗
kid
. In
he copula literature, the most common approach is to build it up
rom bivariate component distributions, often using vine structures
Bedford and Cooke, 2002; Panagiotelis et al., 2012). However, that
s most convincing when there is a natural ordering of the observed
ariables, particularly temporal sequencing (as in the application
y Panagiotelis et al., 2012 to a sequence of four observations on
eadache spaced through the day). In our case, although the com-
onent items of EQ-5D-5L were asked in sequence and then the
tems of EQ-5D-3L later in the questionnaire, that ordering does
ot correspond at all to the natural connections between the 3L and
L items through their shared meaning. For that reason, we  adopt
 different approach, using ﬁve separate bivariate copulas for the
ve domains of EQ-5D, and connecting the domains via a latent
actor V which represents common inﬂuences on the respondent’s
esponses. The error Ukid is decomposed into the latent factor Vi and
 speciﬁc error εkid correlated within but not between domains:
kid = kdVi + εkid (3)
here the  kd are a set of ten parameters. We  make the standard
ssumptions that, conditional on Xi: Vi is independent of all the
kid; the εkid are all mutually independent, except that ε3id, ε5id are
ossibly dependent within any health domain d.
We use a copula representation to capture dependence between
he 3L and 5L responses for any domain. Suppressing the i subscript,
eﬁne Fd(ε3d, ε5d) as the distribution function (df) for domain d and
3d(ε3d) = Fd(ε3d, ∞)  and F5d(ε5d) = Fd(∞, ε5d) to be the marginals.
heir joint df for domain d is speciﬁed as:
d(ε3d, ε5d) = cd(G3d(ε3d), G5d(ε5d); d) (4)
here Gkd(·) is the marginal df of εkd and d is a parameter con-
rolling the dependence between ε3d and ε5d. The function cd(·) is
nown as a copula and, together with the marginals G3d(·), G5d(·) it
niquely characterises the bivariate distribution of ε3d, ε5d. It has
he properties cd(0, u) = cd(u, 0) = 0 and cd(1, u) = cd(u, 1) = u for any
 ≤ u ≤ 1 (Trivedi and Zimmer, 2005). We  consider the following
andidate forms:
aussian : c(ε3, ε5) = (−1(ε3), −1(ε5); )ealth Economics 55 (2017) 139–152 143
where (., .;) is the distribution function of the bivariate normal
with correlation coefﬁcient −1 ≤  ≤ 1 and −1(·) is the inverse of
the univariate N(0, 1) df
Clayton : c(ε3, ε5) =
{[
max
{
ε−3 + ε−5 − 1, 0
}]−1/
for 0 <  ≤ ∞
ε3ε5 for  = 0
Frank : c(ε3, ε5) =
⎧⎨
⎩ −
1

ln
(
1 +
(
e−ε3 − 1
)(
e−ε5 − 1
)
e− − 1
)
for  /= 0
ε3ε5 for  = 0
Gumbel : c(ε3, ε5) = exp
(
−
[
(− ln ε3) + (− ln ε5)
]1/)
for  ≥ 1
Joe  : c(ε3, ε5) = 1 −
[
(1 − ε3) + (1 − ε5) − (1 − ε3)(1 − ε5)
]1/
for  ≥ 1
The Gaussian and Frank copulas are similar in that both allow for
positive or negative dependence, symmetric in both tails, but the
Frank form generates dependence weaker in the tails and stronger
in the centre of the distribution. The Clayton copula allows only pos-
itive dependence, with strong left tail dependence and relatively
weak right tail dependence; thus, if two  variables are strongly cor-
related at low values but less so at high values, then the Clayton
copula is a good choice. To show the effect of copula choice, Fig. 3
shows simulated scatter plots generated using these three copulas.4
The Gumbel and Joe copulas (not illustrated) display weak left tail
dependence and strong right tail dependence, which is stronger for
the Joe than the Gumbel copula.
The within-domain speciﬁcation is completed by a normal mix-
ture assumption which allows any of the errors εkid to have a
non-normal form:
G(ε) = (ε − 1
1
) + [1 − ](ε − 2
2
) (5)
where 0 ≤  ≤ 1 is the mixing parameter; (1, 2) and (1, 2 ≥ 0)
are location and dispersion parameters constrained to satisfy the
mean and variance normalizations 1 + (1 − )2 ≡ 0 and (21 +
21) + (1 − )(22 + 22) = 1. These normal mixtures can capture
a wide range of distributional shapes, including skewness and
bimodality. The mixture (5) can be implemented with various
degrees of generality, by assuming the same parameter values (,
1, 2, 1, 2) for all error terms, or allowing them to vary with
domain d = 1, . . .,  5 and/or EQ-5D design k = 3, 5. We  specify a normal
mixture distribution for the latent factor V also.
Conditional on X, the probability of observing any values Y3d = q
and Y5d = r is:
P(q, r|X, d) = cd(Gkd(q + 1),  Gkd(r + 1)) − cd(Gkd(q + 1),  Gkd(r))
− cd(Gkd(q), Gkd(r + 1)) + cd(Gkd(q), Gkd(r))
(6)
where Gkd denotes Gkd(kqd − Xˇkd). The joint distribution of Y31,
Y51, . . .,  Y35, Y55 is:
Pr(Y31, Y51, . . ., Y35, Y55|X) =
∫ 5∏
d=1
P(Y3d, Y5d|X, v)
[
p
s1
	
(
v − m1
s1
)
+ 1 − p
s2
	
(
v − m2
s2
)]
dv (7)
We  use Gauss–Hermite quadrature with 15 integration points to4 Samples generated by Monte Carlo simulation, from copulas speciﬁed with
Kendall’s 
 ≈ 0.7.
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butions and are in line with the conclusions of the domain-speciﬁc
bivariate models. The estimated coefﬁcients of the domain-speciﬁc
bivariate and joint models are shown in Appendix Table A1.Fig. 3. Pseudo-random samples 
. Modelling results
Our aim is to estimate the joint distribution of the responses
o the 3L and 5L variants of the EQ-5D survey instrument, condi-
ional on demographic characteristics (age and gender), and clinical
easures of the severity of the underlying rheumatic condition. We
se seven covariates: age, gender, the HAQ disability score, the pain
cale, and the squares and product of the HAQ and pain scales.
The HAQ is based on patient self-reporting of the degree of dif-
culty experienced over the previous week in eight categories:
ressing and grooming, arising, eating, walking, hygiene, reach,
rip, and common daily activities. It is widely used by clinicians
o measure health outcomes. It is scored in increments of 0.125
etween 0 and 3 (although it is standard to consider it fully continu-
us), with higher scores representing greater degrees of functional
isability. The HAQ instrument also includes separately a patient
elf-report of pain scored on a Visual Analogue Scale (0–10).
.1. Domain-speciﬁc modelling
We  start by examining each of the ﬁve domains of EQ-
D separately using a bivariate approach, implemented in the
ernández-Alava and Pudney (2016) Stata bicop routine. There
re several reasons for this: it is computationally easier to make the
hoice of copula for each domain separately, and the process gener-
tes good parameter starting values for likelihood optimisation for
he full model. Also, although conditional independence between
omains is rather implausible, if independence is not rejected, or
f it turns out to have little adverse impact on cost-effectiveness
pplications, then domain-speciﬁc modelling offers a simple and
ffective approach.
Table 3 summarises the sample ﬁt of alternative copula func-
ions for the 3L- and 5L variants for each of the ﬁve domains, where
e retain the standard assumption of Gaussian marginals. There
s no single best choice of copula: the Gaussian form ﬁts best for
imensions 1 and 3 (mobility and usual activities), the Frank copula
ts best for dimensions 2 and 5 (self-care and anxiety/depression)
hile the Gumbel copula ﬁts best for the pain/discomfort dimen-
ion. This coincides with differences in the empirical distributions
f Fig. 1 between these three groups of domains. The Frank copula
which allows weaker dependence in the tails than the centre of
he distribution) works better than the Gaussian copula when the
ails of the response distribution are relatively heavy. The Gum-
el copula which has asymmetric dependence in the tails (stronger
ependence at higher values) ﬁts better when there is a central
ode and implies different patterns of dependence in both tails of
he distribution.
Table 3 also gives the results of the Wald test of the null hypoth-
sis that the coefﬁcient vectors relating the (latent) response to age, from three alternative copulas.
gender and disease severity are identical in the 3- and 5L variants.
The hypothesis is clearly rejected for the domains of mobility and
pain. This ﬁnding shows that the effect of the move to 5 levels is
not simply a uniform re-alignment of the response level.5
The assumption of normal marginals for the errors εkd was
acceptable in terms of the Akaike (AIC) and Bayesian (BIC) infor-
mation criteria for the mobility, self-care and anxiety/depression
domains, but there was signiﬁcant evidence of modest depar-
tures from normality for the usual activities and pain/discomfort
domains. Table 4 summarises the preferred speciﬁcations for those
two domains, comparing them with the simpler Gaussian-marginal
models. Note that the conclusions about the equality of coefﬁcients
are not affected by non-normality.
Fig. 4 plots the estimated distributions for the two domains
where we  ﬁnd signiﬁcant non-normality, and compares them to
the N(0, 1) form. The distributions for the usual activities domain
and for the EQ-5D-5L pain/anxiety domain are similar, both with a
slightly fatter right tail of the distribution. The distribution for the
EQ-5D-3L pain/anxiety dimension departs from normality with a
much bigger central mode, consistent with its unique distributional
shape in Fig. 1.
4.2. Joint modelling of all domains
We  now examine the joint model. Table 5 summarises the sam-
ple ﬁt of alternative joint models. All of them are based on the best
ﬁtting copulas for each dimension found in Section 4.1: Gaussian
for mobility and usual activities; Frank for self-care and anxi-
ety/depression; and Gumbel for pain/discomfort. Model (a) is the
baseline model with no mixtures in ε; model (b) allows a common
mixture, constrained to be the same for the errors in all ten equa-
tions; and model (c) allows for one common mixture for the usual
activities domain and different mixtures for the 3L and 5L equa-
tions for pain/discomfort, following the pattern in Table 3. The joint
log-likelihood, AIC and BIC for the model with independent EQ-5D
dimensions are −29,958.431, 60,144.86 and 60,892.12 respectively,
indicating that the joint model provides a better ﬁt to the data. The
joint model with a common mixture, model (b), gives the best ﬁt
to the data according to AIC and BIC. The conclusions about the
equality of coefﬁcients are not affected by the choice of error distri-5 Note that these are formally tests of the hypothesis that the coefﬁcient vectors
are  equal after each error variance is normalised to unity. Since the extreme points
on  the 3L and 5L scales are (mostly) given the same verbal labels to act as anchors, the
assumption seems reasonable. Also, where differences are statistically signiﬁcant,
the 3L and 5L coefﬁcient vectors are clearly not scalar multiples of each other.
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Table  3
Sample ﬁt of domain-speciﬁc models for alternative copula functions with Gaussian marginals.
Copula
Gaussian Frank Clayton Gumbel Joe
Mobility domain
Log-likelihood −6656.54 −6665.73 −6727.46 −6669.82 −6736.73
2(7) for H0: ˇ3 = ˇ5 29.02*** 29.49*** 23.82*** 33.64*** 37.14***
Self-care domain
Log-likelihood −4221.35 -4212.35 −4248.89 §  §
2(7) for H0: ˇ3 = ˇ5 8.31 5.98 5.35
Usual activities domain
Log-likelihood −6772.96 −6796.04 −6866.11 −6785.64 −6829.65
2(7) for H0: ˇ3 = ˇ5 10.87 10.22 10.89 11.23 11.53
Pain/discomfort domain
Log-likelihood −6148.63 −6148.07 −6190.84 −6147.80 −6199.63
2(7) for H0: ˇ3 = ˇ5 29.75*** 30.26*** 32.71*** 29.09*** 26.82***
Anxiety/depression domain
Log-likelihood −6243.59 −6238.86 −6300.55 −6244.72 −6302.70
2(7) for H0: ˇ3 = ˇ5 12.05* 8.56 5.10 10.66 11.86
Best-ﬁtting models in bold type (all models have 15 parameters).
* Statistical signiﬁcance: 10%.
*** Statistical signiﬁcance: 1%.
§ No convergence.
Table 4
Estimated non-normal error distributions.
Domain Gaussian marginals Non-Gaussian marginals
AIC BIC Preferred mixture speciﬁcation AIC BIC Coefﬁcient equality test: 2(7)
Usual activitiesa 13587.9 13725.5 Equal 13550.5 13707.8 8.39
Pain/discomfortb 12337.6 12475.3 Unequal 12252.9 12429.9 40.91***
a Gaussian copula.
b Gumbel copula.
*** Statistical signiﬁcance: 1%.
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Fig. 5 illustrates the effect of the differences in the distribu-
ion functions (df) of the latent variables Y∗
ikd
, evaluated at the
ample mean values of the indexes Xi ˆˇ kd. These dfs calculated
or the 3L and 5L equations are similar for the self-care, anxi-
ty/depression and (to a lesser degree) usual activities domains.
oreover, the two threshold parameters for the 3L model fall
espectively between the bottom two, and top two  thresholds in
he 5L model (ˆ52d < ˆ32d < ˆ53d and ˆ54d < ˆ33d < ˆ55d), which
s consistent with the idea of a simple re-alignment of responses.
owever, for the mobility and pain/discomfort domains, the dif-
erences between dfs are sizeable and statistically signiﬁcant, with
he pain/discomfort domain displaying the largest difference. For
oth mobility and pain/discomfort, one of the 3L threshold param-
ters lies outside the range covered by the 5L threshold parameters,
hich is inconsistent with the simple realignment hypothesis.al activities and pain/discomfort domain.
5. Mapping
The best method of mapping between alternative preference-
based measures depends on the nature of the cost-effectiveness
study in which the measure is to be used. Suppose, for example,
that the study is to be done on the new 5L basis, but the available
evidence comes from a clinical trial in which the older EQ-5D-
3L scale is measured. The key concept is the mean QALY, which
should be constructed as E{Q(5(Y5))}, where E{ · } is the expecta-
tion with respect to whatever population is potentially affected by
the treatment.
There are two technical issues to be considered in mapping from
3L evidence to 5L-based evaluation. First, the form of the function,
Q(·), which maps utilities into QALYs. In most evaluation studies,
the QALY calculation Q(·) is a linear function of the utilities, so that
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Table  5
Sample ﬁt of joint copula models.
Type of mixture in ε
(a) None (b) Equal (c) Unequal
Log-likelihood −29197.46 −29136.23 −29132.50
Number of parameters 115 118 124
AIC  58624.91 58508.46 58513.00
BIC  59378.73 59281.93 59325.80
Coefﬁcient equality
Mobility domain
Equality of  ˇ 2(7) 26.59*** 26.53*** 25.69***
Equality of  2(1) 0.18 0.29 0.00
Equality of  ˇ and  2(8) 28.59*** 26.53*** 28.73***
Self-care domain
Equality of  ˇ 2(7) 4.14 3.50 3.99
Equality of  2(1) 3.02* 3.37* 4.17**
Equality of  ˇ and  2(8) 9.60 8.91 10.80
Usual  activities domain
Equality of  ˇ 2(7) 8.81 7.93 9.39
Equality of  2(1) 0.33 0.21 0.45
Equality of  ˇ and  2(8) 12.77 10.82 11.88
Pain/discomfort domain
Equality of  ˇ 2(7) 31.64*** 30.19*** 36.58***
Equality of  2(1) 18.80*** 21.42*** 29.27***
Equality of  ˇ and  2(8) 46.98*** 50.65*** 66.01***
Anxiety/depression domain
Equality of  ˇ 2(7) 9.27 8.70 9.36
Equality of  2(1) 2.68 2.75* 3.75*
Equality of  ˇ and  2(8) 11.07 10.54 11.99
* Statistical signiﬁcance: 10%.
** Statistical signiﬁcance: 5%.
*** Statistical signiﬁcance: 1%.
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aFig. 5. Estimated distribution functions and cutpoints for
{Q(5(Y5))} = Q(E{5(Y5)}). In other words, we can simply predict
he utility outcome (Y5) and use that prediction in calculating
ALYs. If the predictor is an unbiased (or consistent) estimator
f E[(Y5)], it will give an unbiased (consistent) evaluation of the
xpected QALY.
The second issue is the choice of predictor for (Y5). We have
rgued here that a predictor based on a full model of Pr(Y5|Y3,d Y∗5 (joint model, evaluated at covariate sample means).
X) uses more information and is capable of giving better results
than the alternative approach to mapping, which attempts to
model E(5(Y5)|3(Y3), X) directly – often using methods like linear
regression which are not well suited to the non-standard distribu-
tions involved. When using our approach, it is important to realise
that the utility scales (·) are nonlinear functions of the vector Y, so
E(5(Y5)) /= 5(E[Y5]). We should not map  the observed 3L health
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escription Y3 into the 5L descriptive system Y5 and then apply
he utility scale 5(·). Instead, the appropriate method is to use
he model estimated from NDB data to evaluate the probability of
ach possible conﬁguration of Y5 conditional on Y3, X and use those
robabilities as weights to evaluate the conditional expectation of
. The conditional df of the valuation 5 is:
r(5(Y5) ≤ ϒ|Y3, X) =
∑
Y5 ∈ Uϒ
Pr(Y5|Y3, X) (8)
here Uϒ is the set {Y5:5(Y5) ≤ ϒ}  and ϒ is any given constant.
he mean is:
(5(Y5)|Y3, X) =
∑
Y5 ∈ S5
5(Y5)Pr(Y5|Y3, X) (9)
here S5 is the set of 3125 possible values that the vector Y5 might
ake.6
The choice of covariates is critical here. Mapping from Y3 rather
han direct observation of 5(Y5) introduces no bias in the calcula-
ion of mean QALYs if the conditional mean function E(5(Y5)|Y3,
) in the population represented by the reference sample used for
apping is identical to E(5(Y5)|Y3, X) in the population repre-
ented by the trial subjects. In general, reference samples and trial
amples are drawn in quite different ways, and there is always a
ossibility that the statistical relationship between Y3 and Y5 could
iffer substantially between the two populations, leading to map-
ing bias. The use of covariates can reduce this risk by allowing
or factors which might cause the Y3, Y5 association to differ across
amples. Thus, even if E(5(Y5)|Y3) differs between the reference
nd trial samples, E(5(Y5)|Y3, X) may  not, for a judicious choice of
ovariates. We  explore this in the next section.
Several authors have commented on the loss of variation
nduced by mapping (Brazier et al., 2010; Longworth and Rowen,
011; Fayers and Hays, 2014). The sample variance of the mean pre-
ictor (9) will always be lower than the variance of the unknown
rue 5(Y5), because the modelling process can only predict vari-
tion in 5(Y5) arising from Y3 and X, not the other “unexplained”
omponents of variation. In standard cases where the QALY cal-
ulation is linear in utilities, this does not matter, since only the
onditional mean of  (Y ) is required. If the aim were to estimate5 5
he variance of 5(Y5), one would not do it by using the variance
f the predictor (9); instead, the appropriate method is to calculate
irectly the variance of the distribution (8), which gives a consistent
6 Hernández-Alava and Pudney (2017) provide a Stata command eq5dmap that
mplements variants of this mapping operation.nt domain-speciﬁc bivariate models.
estimate of var(5(Y5)) if the mapping model is correctly speciﬁed
and estimated.
If we  evaluate (8) and (9) at each observation Yi3, Xi, and then
average over the sample, the result is a consistent estimator of
the distribution of 5(Y5) or its mean E[5(Y5)]. This can be done
empirically for the pre-January 2011 waves of the NDB dataset and
in reverse (predicting Y3 conditional on Y5) for the post-January
2011 waves. Fig. 6a uses the set of domain-speciﬁc bivariate models
(assuming independence across domains) to compare the predic-
tive df n−1
∑n
i=1Pr(5(Y5) ≤ ϒ|Yi3, Xi) and the directly-observed
empirical df n−1
∑n
i=11(3(Yi3) ≤ ϒ)  for the Jan 2010 wave of NDB,
where 1( · ) is the indicator function. Fig. 6b makes the reverse com-
parison of the predictive df for 3(Y3) with the empirical df of
5(Y5) for the Jan 2012 wave. Fig. 7 makes the same comparisons
for the joint model allowing for between-domain correlation.
There are two  striking features of Figs. 6 and 7, with important
implications for the economic evaluations carried out for public
bodies like NICE. First, the predictive and actual distributions of
the 5L variant of EQ-5D are similar and much smoother than the
corresponding distributions for the 3L variant. This is an encour-
aging ﬁnding: if a decision maker elects to recommend the use of
the new 5L instrument and associated scoring, it may  be possible to
continue to use older 3L-based evidence with appropriate mapping
to 5L. Second, there is a large difference between the 3L and 5L dis-
tributions of EQ-5D scores, whether directly observed or mapped.
Utility scores tend to be systematically higher under the 5L scor-
ing scheme, so the df for EQ-5D-3L lies entirely to the left of the df
for EQ-5D-5L. If no other adjustment were made, this alone might
be enough to change many evaluation results, in the absence of
offsetting adjustments to the evaluation methodology.
Table 6 shows average values of directly-measured 3(Y3) and
the prediction E[5(Y5)|Y3, X] for the 2010 wave of NDB, and of
the prediction E[3(Y3)|Y5, X] and directly-measured 5(Y5) for
the 2012 wave using the joint model. Results are given for the
whole sample and subgroups deﬁned in terms of disease sever-
ity and demographic characteristics; sample standard deviations of
the measured and predicted utilities are also shown. As expected,
there are higher mean values and smaller standard deviations for
the EQ-5D-5L scores (whether predicted or directly observed) than
for EQ-5D-3L, resulting from the different scoring of poor health
states by the two  value sets. Another consequence of this is the
much steeper severity gradient for the mean EQ-5D-3L utilities than
for EQ-5D.There is a slight tendency for both the 3L and 5L utilities to
decline over time as the health states of those individuals who
appear in both waves tend to worsen. However, the means of
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Fig. 7. Cross-mapping based on the joint model with between-domain correlation.
Table 6
Means and standard deviations of actual and predicted (joint model) EQ-5D-3L and EQ-5D-5L by severity of condition, age and gender (NDB. January 2010 wave n = 3877;
January 2012 wave n = 3911).
January 2010 January 2012
EQ-5D-3L EQ-5D-5L EQ-5D-3L EQ-5D-5L
(actual) (predicted) (predicted) (actual)
Mean (SD) Mean (SD) Mean (SD) Mean (SD)
Overall 0.70 0.79 0.69 0.78
(0.25) (0.16) (0.21) (0.19)
Severity group
Mild 0.88 0.92 0.87 0.92
(HAQ  group 1, Pain group 1) (0.12) (0.04) (0.08) (0.07)
Medium 0.62 0.71 0.61 0.73
(HAQ  group 2, Pain group 3) (0.15) (0.09) (0.11) (0.11)
Severe 0.12 0.38 0.12 0.30
(HAQ  group 3, Pain group 5) (0.29) (0.16) (0.19) (0.23)
Female <65 0.69 0.78 0.68 0.77
(0.26) (0.17) (0.23) (0.20)
Male<65 0.71 0.80 0.67 0.77
(0.25) (0.16) (0.24) (0.21)
Female 65–79 0.71 0.79 0.69 0.79
(0.24) (0.15) (0.20) (0.18)
Male  65–79 0.73 0.82 0.73 0.83
(0.22) (0.14) (0.18) (0.14)
Female ≥ 80 0.65 0.76 0.66 0.76
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The key criterion used in cost-effectiveness analysis is the Incre-
mental Cost-Effectiveness Ratio (ICER), deﬁned as the difference in
costs between two different treatment strategies, expressed as a(0.25) 
Male  ≥ 80 0.74 
(0.17) 
redicted and directly-observed versions of each measure are
emarkably close both overall and in terms of their severity and
emographic proﬁles.
We also see the anticipated smaller standard deviations of the
redicted than directly-observed utilities as a consequence of the
se of expected value prediction. This is of no importance for the
valuation described in the next section (since the criterion is based
n the mean QALY), but it would be a concern for any evaluation
hat aims to investigate the distributional pattern of QALY gains
ithin each population group. In that case, appropriate measures
onstructed from the full distribution (8) would need to be used.
. The impact on cost-effectiveness analysis
We  now use a published cost-effectiveness study to examine the
otential consequences of moving from EQ-5D-3L to EQ-5D-5L as basis for economic evaluation. We  ﬁrst replicate the economic
valuation results in Wailoo et al. (2014), which use EQ-5D-3L
ata collected as part of a trial. Then we repeat the analysis using
Q-5D-5L obtained using the mapping models developed in this(0.17) (0.20) (0.18)
0.83 0.70 0.80
(0.12) (0.17) (0.16)
paper. Wailoo et al. (2014) estimate the cost-effectiveness of com-
binations of disease-modifying anti-rheumatic drugs (DMARDs)
and short-term administration of the steroid prednisolone (PNS),
using data from the 2-year CARDERA trial which involved 467
adult patients with early active RA (less than two  years of disease
duration) in a placebo-controlled factorial design. Two DMARDS
were used in the trial, methotrexate (MTX) and ciclosporin (CS). All
patients received MTX, half received step-down PNS7 and half CS,
generating four treatment groups: (1) monotherapy (MTX only), (2)
combination DMARDs (MTX and CS), (3) DMARD and steroid (MTX
and PNS) and (4) triple therapy (MTX, CS and PNS). Further details
of the methods and clinical effectiveness can be found in Choy et al.
(2008).7 Initially dosed at 60 mg/day, reducing to 7.5 mg/day at 6 weeks and stopped by
34  weeks.
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Table  7
Mean costs, QALYs and incremental cost-effectiveness ratios for the CARDERA trial.
Monotherapy Combination therapies
MTX  MTX+CS MTX+PNS MTX+CS+PNS
Total costsa £7503 £6829 £6323 £6203
EQ-5D-3L from trial data
Total QALYs 1.238 1.093 1.152 1.320
ICER  (for col therapy vs. row therapy)
MTX  only – £4648 £13,714 –£15,929
MTX+CS £4648 – –£8597 -£2765
MTX+PNS £13,714 –£8597 – –£714
EQ-5D-5L mapped from 3L trial data (full joint copula-mixture model)
Total QALYs 1.450 1.351 1.382 1.513
ICER  (for col therapy vs. row therapy)
MTX  only – £6,755 £17,264 –£20,728
MTX+CS £6755 – –£ 16,140 –£3,857
MTX+PNS £17,264 –£ 16,140 – –£917
EQ-5D-5L mapped from 3L trial data for restricted models
Demographic covariates only
Total QALYs 1.437 1.326 1.359 1.480
ICER  (for col therapy vs. row therapy)
MTX  only – £6054 £15,137 –£30,466
MTX+CS £6054 – –£15,198 –£4070
MTX+PNS £15,137 –£15,198 – –£996
Independent domains
Total QALYs 1.462 1.376 1.404 1.531
ICER  (for col therapy vs. row therapy)
MTX  only – £7851 £20,361 –£18,696
MTX+CS £7851 – –£18,179 –£4033
MTX+PNS £20,361 –£18,179 – –£942
Joint  Gaussian model
Total QALYs 1.453 1.353 1.384 1.514
ICER  (for col therapy vs. row therapy)
MTX  only – £6818 £17,409 –£20,708
MTX+CS £6,818 – –£16,324 –£3877
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EMTX+PNS £17,409 –
a Present value of treatment costs over the 2-year experimental period.
atio to the difference in the QALYs that they achieve. Treatments
ith ICERs below a certain threshold are usually considered cost-
ffective. In the UK, NICE guidance on technology appraisal refers to
 speciﬁc range £20,000–£30,000 (NICE, 2013), but see also Claxton
t al. (2015) who argue for a lower threshold.
Resource use (prescription drugs, hospitalizations, tests, imag-
ng, surgical procedures and community care visits) was directly
bserved over the two years of the trial and costed using 2011–2012
gures. The mean discounted cost of each treatment strategy is
hown in the ﬁrst row of Table 7, based on the sample of patients
ith complete data (n = 241). QALY estimates were derived from
Q-5D-3L responses observed at baseline and 6, 12, 18 and 24
onths and the discounted QALY total was estimated as the
rea under the linear interpolation of the ﬁve points. We  then
epeated the QALY estimation using EQ-5D-5L predicted from the
ull mixture-copula model presented in Section 4.2, conditional on
he demographic and clinical covariates and EQ-5D-3 responses
bserved in the trial. Note that, since this construction is a linear
unction of the EQ-5D responses Y, our use of E(Y5|Y3, X) as a pre-
ictor does not introduce bias into the QALY evaluation, as it would
or a nonlinear function of Y.The cost-effectiveness results are presented in the ﬁrst two pan-
ls of Table 7.8 Of the four treatment strategies, triple therapy is the
east costly and most effective, thus dominating all other strate-
8 Note that there are minor differences between the numbers reported in Table 7
nd those in Wailoo et al. (2014) due to missing data in the variables used to predict
Q-5D-5L for one patient, but results are unaffected.24 – –£920
gies. Among the remaining three treatment strategies, the MTS+CS
combination is dominated by MTX  plus steroid, being more costly
and less effective. Monotherapy is more costly but also more effec-
tive than MTX  plus steroid, with an ICER of £13,714 which lies
comfortably below a conventional cost-effectiveness threshold of
£20,000 per QALY. The effect of mapping is to increase the esti-
mated dominance of the triple therapy over all others and also
the dominance of MTX+PNS over MTX+CS. The ICER for monother-
apy versus MTX+PNS increases from £13,714 to £17,264, which
remains below the conventional threshold. Thus, mapping has
increased the magnitude of estimated ICERs, but without changing
any of the decisions that would be likely to follow.
The mapped EQ-5D-5L QALYs are larger (by 15–24%) than the
directly-measured EQ-5D-3L QALY estimates; but critically, they
also vary less proportionately – the range of QALYs is 20% of the
smallest for EQ-5L-3L but 12% for mapped EQ-5D-5L. Because the
QALY is in the ICER denominator, the six ICERs for pairwise compar-
isons of the therapies increase in magnitude – by more than 100%
in some cases. This result is partly due to the signiﬁcant response
differences to the mobility and pain questions, but also to the large
negative values built into the Dolan (1997) utility scoring system
which tends to increase the coefﬁcient of variation of 3L scores rel-
ative to 5L scores. Thus a substantial part of the increase in ICERs
when using mapping is attributable not to mapping per se,  but to
the different structures of the 3L and 5L scoring systems. This sug-
gests that we can expect to see similar results if we adopt EQ-5D-5L
in many other evaluation settings – perhaps warranting a future
reassessment of the cost-effectiveness threshold by bodies such as
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ICE. Preliminary work by Hernández-Alava et al. (2017) tends to
upport this view.
We  can explore the impact of mapping in the remainder of
able 7 by showing the effects on cost-effectiveness results of using
hree alternative simpliﬁed versions of the mapping model. It is
ommon practice in economic evaluation to use very limited sets
f covariates in mapping models; the ﬁrst restricted model investi-
ates this by dropping from the model the ﬁve (highly signiﬁcant)
ovariates based on the HAQ and pain scale clinical measures. Sim-
lifying the covariate list has the effect of greatly increasing the
pparent dominance of the triple therapy over all others, with the
CER relative to monotherapy rising by almost 50% in magnitude.
gain, it is unlikely that cost-effectiveness decisions would differ
rom those made with direct measurement of EQ-5D-3L.
The second simpliﬁed version of the mapping model retains the
ull set of covariates but imposes the restriction of independence
cross health domains by eliminating the random effect V through
he parameter restrictions  kd = 0, which are strongly rejected by
irect tests. Relative to the full mapping model, most ICERs increase
n magnitude under the independence restriction and, in the case
f monotherapy versus the MTX/steroid combination, the increase
akes the ICER beyond the £20,000 threshold, which would bring
he cost-effectiveness of monotherapy into question in a compar-
son between the two. That ICER is almost 50% greater than the
stimate derived from direct observation of EQ-5D-3L.
The third simpliﬁed model retains the full covariate vector and
ross-domain correlation, but imposes normality on the error dis-
ributions by eliminating all mixture parameters and imposing the
aussian copula in all of the ﬁve domains. Here the ICER results are
imilar to those of the full model and consequent cost-effectiveness
ecisions.
The differences between cost-effectiveness estimates derived
rom different versions of the mapping model are potentially large
nough to alter policy decisions. For example, the ICER comparing
onotherapy with combination DMARD + steroid rises by 18% from
17,264 to £20,361 when we switch to the independent domains
odel. If we were to use a cost-effectiveness threshold of £20,000,
his would question the decision that monotherapy is cost-effective
elative to the DMARD + steroid combination therapy. Using the
oint model, the ICER rises to £17,264, not large enough to reverse
he decision but a substantial rise nonetheless.9 Since the ICER is the
atio of a cost difference to a QALY difference, it is particularly sen-
itive to changes in the denominator when alternative treatments
ave similar impacts on QALYs.
. Conclusions
There are three clear conclusions. First, econometric modelling
ased on a ﬂexible mixture-copula speciﬁcation has revealed sig-
iﬁcant differences between the 3L and 5L versions of the EQ-5D
escriptive system for health states. These differences are partic-
larly striking for the mobility and pain domains, where the two
ersions of the instrument give signiﬁcantly different pictures of
he relationship between individual health states and their demo-
raphic and clinical determinants.
Second, we have developed a new and powerful technique for
odelling and mapping between the 3L and 5L health descrip-
ions provided by the two variants of EQ-5D, using a conditional
xpectation approach. In this framework, we map  between health
escriptive systems before applying utility scores, and this mapping
rocedure reproduces the directly-observed distributional shape
uite faithfully. On the basis of the evidence presented here, NICE
9 The ﬁrst published version of the value set (Devlin and van Hout, 2015) produced
igher ICERs, £21,476 and £18,100 respectively.ealth Economics 55 (2017) 139–152
could move to the new 5L version of EQ-5D as the basis for its
decision-making, and use ﬂexible mapping techniques where nec-
essary to convert old 3L evidence to the new basis. The alternative
approach of direct mapping between utility scores can reproduce
distributional features accurately if a sufﬁciently ﬂexible model is
speciﬁed (Hernández-Alava et al., 2012), but that approach ignores
the richer information available in the health descriptions Y31, . . .,
Y35 and Y51, . . .,  Y55 and does not allow comparisons to be made
across domains. Perhaps most importantly, the direct approach
conﬂates the effect of the redesigned health description and the
revised utility tariff and does not offer a natural way of comparing
alternative utility tariffs.
Third, our re-examination of evidence from a trial of combina-
tion drug therapies for rheumatoid arthritis shows that switching to
the newer 5L version of EQ-5D and using the utility scoring system
recently proposed by Devlin et al. (2016) can make a substantial dif-
ference to the conclusions from cost-effectiveness studies. This is
partly a consequence of the different utility tariffs developed for EQ-
5D-3L and EQ-5D-5L which itself may  call for some adjustment to
the way that such studies are translated into funding decisions. But,
working within a comprehensive and ﬂexible framework that mod-
els 3L and 5L jointly, we have shown that econometric speciﬁcation
can also have a separate large impact. In particular, making the
simplifying assumption of independence across health domains, or
using a restricted set of covariates that excludes clinical informa-
tion, may  cause large shifts in cost-effectiveness ratios – of up to
50% in our application to rheumatic disease.
Appendix A. Full parameter estimates
Table A1
Estimated coefﬁcients of the domain-speciﬁc bivariate and joint models.
Domain-speciﬁc model Joint model
Coefﬁcient Std. error Coefﬁcient Std. error
Mobility domain – 3 levels
Male 0.4601 0.0543 0.5125 0.0637
Age/10 −0.0117 0.0169 −0.0067 0.0197
Pain/10 2.4178 0.3205 2.8928 0.3826
HAQ  1.2370 0.1092 1.3765 0.1347
HAQ2 −0.9591 0.3880 0.0987 0.0627
Pain2 0.0593 0.0522 −1.2067 0.4554
HAQ  × pain −0.3067 0.1603 −0.3134 0.1907
  0.6494 0.0416
1 1.8996 0.1244 2.2583 0.1547
2 5.6557 0.1634 6.7752 0.2465
Mobility domain – 5 levels
Male 0.3390 0.0430 0.3839 0.0504
Age/10 0.0506 0.0137 0.0612 0.0159
Pain/10 1.9446 0.2525 2.4359 0.2964
HAQ  1.2235 0.0841 1.4009 0.1010
HAQ2 −0.4122 0.3099 0.0610 0.0470
Pain2 0.0458 0.0397 −0.6556 0.3606
HAQ  × pain −0.3969 0.1283 −0.4656 0.1527
  0.6279 0.0317
1 1.5939 0.0982 1.8964 0.1184
2 2.9367 0.1032 3.4302 0.1321
3 4.2711 0.1093 4.9911 0.1511
4 5.5625 0.1303 6.5589 0.1920
Dependency  0.7074 0.0139 0.5956 0.0203
Self-care domain – 3 levels
Male 0.6103 0.0662 0.6438 0.0688
Age/10 −0.1067 0.0204 −0.1096 0.0210
Pain/10 1.0591 0.4462 1.4948 0.4722
HAQ  1.8555 0.1966 1.9641 0.2226
HAQ2 −0.6821 0.4457 −0.0444 0.0790
Pain2 −0.0314 0.0729 −1.0048 0.4603
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Table  A1 (Continued)
Domain-speciﬁc model Joint model
Coefﬁcient Std. error Coefﬁcient Std. error
HAQ × pain 0.0428 0.2036 0.0040 0.2144
  0.3163 0.0347
1 2.7358 0.1960 2.9350 0.2235
2 5.7598 0.2142 6.1590 0.2565
Self-care domain – 5 levels
Male 0.6366 0.0536 0.6779 0.0569
Age/10 −0.0949 0.0167 −0.1006 0.0175
Pain/10 1.2139 0.3390 1.7335 0.3669
HAQ 1.5870 0.1270 1.7245 0.1432
HAQ2 −0.7787 0.3644 0.0097 0.0561
Pain2 0.0182 0.0519 −1.1726 0.3852
HAQ × pain 0.0764 0.1583 0.0276 0.1686
  0.3806 0.0289
1 2.0816 0.1350 2.3131 0.1524
2 3.4855 0.1399 3.7768 0.1627
3 4.9402 0.1512 5.3745 0.1825
4 5.6903 0.1729 6.3115 0.2176
Dependency  6.0530 0.3145 5.5022 0.3051
Usual activities domain – 3 levels
Male 0.2409 0.0539 0.3278 0.0781
Age/10 −0.0582 0.0168 −0.0751 0.0240
Pain/10 2.6254 0.3175 4.1937 0.4879
HAQ 1.7515 0.1164 2.6488 0.1936
HAQ2 −1.3382 0.3756 −0.3058 0.0709
Pain2 −0.1891 0.0503 −2.1676 0.5438
HAQ × pain 0.0196 0.1594 −0.1170 0.2237
  1.0333 0.0819
1 1.7532 0.1278 2.7194 0.2159
2 4.7465 0.1520 6.9414 0.3559
Usual activities domain – 5 levels
Male 0.1923 0.0440 0.2462 0.0625
Age/10 −0.0751 0.0139 −0.0961 0.0195
Pain/10 2.4151 0.2616 3.7146 0.3862
HAQ 1.6059 0.0925 2.2971 0.1437
HAQ2 −1.3418 0.3149 −0.1997 0.0581
Pain2 −0.1386 0.0416 −2.0802 0.4497
HAQ × pain 0.0367 0.1325 −0.0395 0.1881
  0.9943 0.0616
1 1.0144 0.0997 1.5766 0.1490
2 2.4708 0.1074 3.6049 0.1854
3 3.9116 0.1188 5.6372 0.2345
4 4.8488 0.1342 6.8882 0.2712
Dependency  0.5560 0.0172 0.1019 0.0541
Common mixture
 0.0621 0.0461
1  −  0.9379 0.0461
1 0.2841 0.4314
2 −0.0188 0.0217
21 3.0482 0.8537
22 0.8587 0.0665
Pain/discomfort domain – 3 levels
Male 0.1737 0.0472 0.2130 0.0562
Age/10 0.0332 0.0156 0.0274 0.0181
Pain/10 6.3976 0.4445 7.1520 0.4037
HAQ 0.6059 0.0908 0.7806 0.1046
HAQ2 −2.3849 0.4493 −0.1176 0.0551
Pain2 −0.1296 0.0488 −3.0418 0.4349
HAQ × pain 0.4015 0.1796 0.1717 0.1849
  0.3705 0.0325
1 0.8379 0.1132 0.9465 0.1241
2 5.1633 0.1728 5.4769 0.1890
  0.5871 0.0787
1  −  0.4129 0.0787
1 −0.0936 0.0528
2 0.1331 0.0771
21 0.2850 0.0824
22 1.9866 0.2359
Pain/discomfort domain – 5 levels
Male 0.1085 0.0424 0.1278 0.0484
Age/10 −0.0504 0.0137 −0.0605 0.0155
Pain/10 6.0189 0.2887 6.9250 0.3362
Table A1 (Continued)
Domain-speciﬁc model Joint model
Coefﬁcient Std. error Coefﬁcient Std. error
HAQ 0.6694 0.0819 0.7903 0.0936
HAQ2 −2.6218 0.3451 −0.1119 0.0460
Pain2 −0.1042 0.0402 −3.0565 0.3848
HAQ × pain 0.3632 0.1391 0.3352 0.1563
  0.5364 0.0301
1 −0.3351 0.0939 −0.3981 0.1061
2 2.0121 0.1049 2.3200 0.1212
3 4.1984 0.1174 4.7505 0.1437
4 5.3824 0.1280 6.0899 0.1616
  0.1075 0.0745
1  −  0.8925 0.0745
1 0.1204 0.1985
2 −0.0145 0.0195
21 2.6886 0.7068
22 0.7948 0.0830
Dependency  1.7094 0.0474 1.5660 0.0452
Anxiety/depression domain – 3 levels
Male 0.0387 0.0491 0.0469 0.0495
Age/10 −0.1350 0.0148 −0.1355 0.0152
Pain/10 1.2087 0.2829 1.3453 0.2894
HAQ 0.4322 0.0904 0.4549 0.0923
HAQ2 −0.2623 0.3495 −0.0663 0.0440
Pain2 −0.0580 0.0436 −0.4026 0.3550
HAQ × pain 0.1788 0.1471 0.1903 0.1478
  0.3257 0.0259
1 0.4435 0.1033 0.4901 0.1055
2 2.2668 0.1086 2.3920 0.1164
Anxiety/depression domain – 5 levels
Male −0.0137 0.0453 −0.0071 0.0462
Age/10 −0.1456 0.0137 −0.1482 0.0142
Pain/10 1.2094 0.2554 1.3614 0.2640
HAQ 0.3731 0.0826 0.4139 0.0855
HAQ2 −0.4111 0.3179 −0.0526 0.0410
Pain2 −0.0387 0.0401 −0.5557 0.3251
HAQ × pain 0.2730 0.1354 0.2818 0.1377
  0.3554 0.0240
1 0.1154 0.0945 0.1625 0.0979
2 1.0888 0.0953 1.1589 0.0999
3 2.0811 0.0998 2.2051 0.1076
4 2.6195 0.1098 2.8087 0.1227
Dependency  14.4849 0.5894 13.9413 0.5912
Common mixture – joint model
 0.0250 0.0127
1  −  0.9750 0.0127
1 −0.5004 0.2528
2 0.0128 0.0072
21 5.6660 1.6944
22 0.8739 0.0286
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